Takeda’s Bet on Cancer Vaccine Fails, Company Loses Millions
Cell Genesys and Takeda terminated their development and commercialization agreement for the GVAX cancer vaccine after Takeda spent $73.9 million on the partnership.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.